Summary of standard usage, dosage and precautions of selumetinib

Selumetinib is a selective MEK1/2 inhibitor that is a targeted therapy drug that mainly acts on the RAS/RAF/MEK/ERK signaling pathway and is used to treat a variety of malignant diseases driven by abnormal activation of this signaling pathway. Currently, selumetinib has been approved by the U.S. FDA for the treatment of pediatric patients with neurofibromatosis type 1 (NF1) and unresectable plexiform schwannoma. A large number of clinical studies have also been conducted in other cancer types. The following will introduce in detail the recommended usage and dosage of selumetinib and the precautions during its use to help patients use the drug safely and effectively.

1. Recommended usage and dosage suggestions

The dose of selumetinib varies based on patient age, weight, indications and individual tolerance. For the treatment of NF1-associated plexiform schwannoma in children, the recommended dose is 25 milligrams per square meter of body surface area taken orally twice daily. The usual dosage interval is 12 hours, and the medication should be taken at the same time every day to maintain stable blood concentrations. The medication should be taken away from food. It is recommended to take it on an empty stomach, that is, 1 hour before eating or 2 hours after eating to ensure the drug absorption effect.

For use in adult patients or in other cancer types (e.g., melanoma, lung cancer, etc.), specific doses may vary depending on study or clinical trial design. The general dosage is between 50mg and 75mg twice a day. The specific dosage needs to be evaluated by a doctor and determined based on individual conditions. The dosage cannot be changed without authorization.

To take the medicine, swallow the tablet whole. Do not break, crush or dissolve it to avoid affecting the drug release mechanism. If the patient takes medication for more than 6 hours, it is recommended to skip the dose and continue to take the next dose at the original time point. Do not double the dose.

2. Precautions during treatment

1.Liver function monitoring

Selumetinib may cause liver function abnormalities, including ALT and AST elevations. Therefore, liver function tests need to be performed regularly before, during and after treatment. If significant transaminase elevation or jaundice occurs, the drug should be discontinued promptly and evaluated whether to adjust the dose or discontinue treatment.

2.Visual problem monitoring

Some patients may experience uncomfortable symptoms such as blurred vision, dry eyes, and decreased vision while using selumetinib, which may be related to retinal detachment or optic neuritis. If there are any changes in vision during use, you must immediately notify your doctor for an eye examination, and if necessary, suspend or terminate the medication.

3.Heart function assessment

Selumetinib may cause a decrease in left ventricular ejection fraction (LVEF), especially when combined with other anticancer drugs. It is recommended to conduct a baseline cardiac function assessment before medication and to review it regularly during treatment. If symptoms of heart failure such as chest tightness, dyspnea or edema occur, the drug should be stopped immediately and treated.

4.Management of skin and mucous membrane side effects

Common adverse reactions include rash, mouth ulcers, dryness, and nail cracks. Most of these side effects are reversible, but they have a greater impact on quality of life. It is recommended that patients moisturize their skin, use mild skin care products, and avoid irritating foods in oral care. If necessary, topical treatment ointments or oral gels can be used under the guidance of a doctor to relieve discomfort.

5.Digestive system reaction

Some patients will experience gastrointestinal symptoms such as nausea, vomiting, and diarrhea, especially in the early stages of treatment. It is recommended to drink plenty of water, avoid spicy and greasy food, and use antidiarrheal or anti-nausea medications as directed by your doctor to control symptoms while taking the medication. If severe and persistent diarrhea occurs, discontinuation of the drug should be considered and the risk of dehydration should be assessed.

6. Medication compliance and education

As an oral targeted drug, patients need to maintain good medication compliance to achieve maximum efficacy. Family members should help children take the medicine on time and in the right amount. If they do not want to stop taking the medicine or miss a dose due to discomfort, they should consult a doctor in time and should not stop taking the medicine or change the dosage on their own.

3. Pay attention to medication for special groups of people

1. Medication for children

Selumetinib is currently mainly used in childrenNF1 patients, so the dose needs to be accurately calculated based on body surface area to avoid overdose or deficiency. Pediatric patients need to closely monitor growth and development, liver and kidney function, blood routine and other indicators during medication.

2.Contraindicated during pregnancy and lactation

Due to the potential teratogenic risk of selumetinib to the fetus, women should avoid pregnancy during treatment and for at least 1 weeks after stopping the drug, and men should also take contraceptive measures. Breastfeeding women should suspend breastfeeding while taking the drug.

3.Be cautious when using combined medications

Selumetinib mainly passes through the bodyCYP3A4Metabolism, therefore when used together with CYP3A4 inhibitors or inducers (such as ketoconazole, rifampicin) may affect blood concentration, special attention should be paid to drug interactions.

Selumetinib, as an innovative targeted drug, has good prospects in the treatment of NF1 related tumors and other tumors characterized by abnormalities in the MAPK pathway. However, due to its potential effects on multiple organ systems, dosage recommendations must be strictly followed during clinical use and treatment must be conducted under the guidance of a physician. Only by strengthening communication between patients and doctors, regularly monitoring indicators, and actively responding to side effects can we achieve dual guarantees of treatment effects and quality of life. For patients with medication needs, it is recommended to complete a comprehensive evaluation in a regular hospital and follow professional guidance for long-term management.

Reference materials:https://www.drugs.com